Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001123292-24-000417
Filing Date
2024-12-27
Accepted
2024-12-27 17:23:14
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 8390
2 EXHIBIT 1 JOINT FILING AGREEMENT sec_jointfilingagmt.htm EX-1 12345
  Complete submission text file 0001123292-24-000417.txt   22539
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Subject) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91051 | Film No.: 241586405
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 195 ARCH. MAKARIOS III AVE. NEOCLEOUS HOUSE LIMASSOL G4 3030
Business Address 195 ARCH. MAKARIOS III AVE. NEOCLEOUS HOUSE LIMASSOL G4 3030 3-572-511-0165
Skorpios Trust (Filed by) CIK: 0001869333 (see all company filings)

EIN.: 000000000 | State of Incorp.: G4 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A